Update on current and potential nanoparticle cancer therapies

Jonathan S. Rink, Michael P. Plebanek, Sushant Tripathy, C. Shad Thaxton*

*Corresponding author for this work

Research output: Contribution to journalReview article

37 Scopus citations

Abstract

PURPOSE OF REVIEW: To summarize the most recent preclinical and clinical advancements in therapeutic nano-oncology. RECENT FINDINGS: First-generation nanotherapies are well tolerated in humans and evidence shows that they are efficacious, while at the same time reducing the burden of side-effects. Most of these therapies are not specifically targeted, but take advantage of enhanced passive accumulation within tumors to preferentially deliver chemotherapies that demonstrate off-target toxicities when administered as free drugs. Also, actively targeted nanotherapies are entering the clinical arena and preliminary data are encouraging. Finally, a number of exciting preclinical developments in nanotechnology provide clear evidence that nanotherapies will continue to enter the clinic and will have a significant impact in oncology. SUMMARY: A number of intriguing nanoparticle therapies are being tested in preclinical and clinical trials. Nanoparticles with increasing molecular sophistication, specific targeting properties, and unique mechanisms of action will find their way to the clinic. Certainly, nanoparticle-based therapies will be increasingly represented in drug development pipelines, and will continue to provide efficacious and well tolerated drug options for patients with cancer.

Original languageEnglish (US)
Pages (from-to)646-651
Number of pages6
JournalCurrent opinion in oncology
Volume25
Issue number6
DOIs
StatePublished - Nov 1 2013

Keywords

  • chemotherapeutic
  • lipoprotein
  • nanoparticle
  • siRNA
  • targeted drug delivery

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Update on current and potential nanoparticle cancer therapies'. Together they form a unique fingerprint.

  • Cite this